Long-term effects of hearing intervention on brain health in the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) randomized study
老年人衰老和认知健康评估 (ACHIEVE) 随机研究中听力干预对大脑健康的长期影响
基本信息
- 批准号:10418325
- 负责人:
- 金额:$ 412.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-15 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AdultAffectAgeAgingAlzheimer&aposs disease related dementiaAlzheimer&aposs disease riskBrainClinicalCognitiveCognitive agingComplementControl GroupsCountyDataDementiaEducationElderlyEvaluationFollow-Up StudiesHealthHealth EducatorsHealth ExpendituresHealthcareHearingHearing AidsHeterogeneityImpaired cognitionInterventionLong-Term EffectsMeasuresMediator of activation proteinMedicalMedicare claimObservational StudyOutcomeParticipantPathologicPathway interactionsPeripheralPhasePoliciesPopulationRandomizedRehabilitation therapyRiskRoleScheduleServicesSeveritiesSiteSocial FunctioningStructureTechnologyTimeTrainingVisitWashingtonbrain healthbrain magnetic resonance imagingbrain volumeclinical carecognitive loadcohortdementia riskfollow-uphealthy aginghearing impairmenthearing loss treatmentmild cognitive impairmentmodifiable risknovel strategiesprimary outcomerandomized trialrecruitsocial engagementsoundtreatment effectwhite matter
项目摘要
Novel approaches to reduce the risk of cognitive decline and Alzheimer's disease and related dementias (ADRD)
in older adults are urgently needed given the aging of the population. Over the past decade, observational
research has implicated peripheral hearing loss as being one of the largest potentially modifiable risk factors for
dementia that may account for 8-9% of all dementia cases. Hypothesized pathways underlying this observed
association may be modifiable with hearing loss treatment consisting of the use of hearing technologies (e.g.,
hearing aids) and rehabilitative training. The Aging & Cognitive Health Evaluation in Elders (ACHIEVE) study is
an ongoing, NIA-sponsored Phase III RCT (R01AG055426, MPIs: Lin/Coresh) investigating whether hearing
loss treatment versus an aging education control intervention reduces cognitive decline over a three-year follow-
up period. From 2018-19, we recruited 977 adults ages 70-84 with untreated mild-to-moderate hearing loss who
were randomized 1:1 at baseline (Year 0) to receive hearing intervention (HI; best-practice hearing services and
technologies) versus a successful aging (SA) education control intervention (i.e., one-on-one sessions with a
health educator covering topics important for healthy aging). Participants are currently being followed
semiannually at the ACHIEVE field sites with final Year 3 study visits scheduled from 2021-22. After their Year 3
visit, all participants randomized to the SA education control group will also be offered the hearing intervention.
Final Year 3 results from this original trial will indicate whether hearing intervention (versus a successful aging
control intervention) reduces cognitive decline over a 3-year interval after randomization. We now propose to
continue following the ACHIEVE cohort for an additional 3 years (i.e., up to Year 6) to determine the long-
term effects of hearing intervention (i.e., participants randomized to HI at Year 0) versus successful
aging/delayed HI control (i.e., participants randomized to SA at Year 0 and offered HI after their Year 3
visit) on cognitive and brain outcomes. Given that cognitive impairment typically reflects the slow
accumulation of pathologic changes, the benefits of HI in slowing this decline may not be fully appreciable within
just 3 years. Therefore, this 6-year follow-up of the cohort will allow us to fully evaluate the longer, cumulative
impact of HI on older adults. Such findings will complement the main trial results in 2023 and directly inform
clinical and policy decisions around the potential use of hearing interventions to reduce the risk of ADRD. This
proposed study has the following aims: Aim 1 To determine the long-term effect of HI versus SA/Delayed HI
control on rates of the co-primary outcomes of: (a) cognitive decline and (b) incident mild cognitive impairment
(MCI)/dementia. Aim 2 To determine the long-term effect of HI versus SA/Delayed HI control on changes in
brain MRI measures of: (a) regional brain volumes and (b) white matter tract integrity. Secondary Aims: 1) To
investigate potential factors contributing to HI treatment effect heterogeneity; 2) To investigate health care
expenditures and utilization between the HI vs SA/Delayed HI control groups by analyzing Medicare claims data.
减少认知衰退、阿尔茨海默病和相关痴呆风险的新方法(ADRD)
鉴于人口老龄化,老年人迫切需要更多的老年人。在过去的十年里,观察性的
研究表明,外周听力损失是患耳聋的最大潜在可修改风险因素之一
痴呆症可能占所有痴呆症病例的8%-9%。观察到的这一现象背后的假设路径
关联可以与包括使用听力技术的听力损失治疗一起修改(例如,
助听器)和康复训练。老年人老龄化和认知健康评估(ACACHE)研究是
正在进行的、由NIA赞助的第三阶段RCT(R01AG055426,MPIS:LIN/Coresh)调查听力是否
失落治疗与老龄化教育控制干预相比,在三年的随访中减少了认知能力的下降
上行期。从2018-19年,我们招募了977名年龄在70-84岁之间的未经治疗的轻度至中度听力损失的成年人,他们
在基线(0年)时随机进行1:1的听力干预(HI;最佳实践听力服务和
技术)与成功的老龄化(SA)教育控制干预(即,与
健康教育者,介绍对健康老龄化重要的主题)。参与者目前正在被跟踪
每半年在ACESS外地站点进行一次考察,计划在2021-22年进行第三年的最后一次考察访问。在他们第三年之后
访问期间,随机分为SA教育对照组的所有参与者也将接受听力干预。
这项原始试验的最终3年结果将表明听力干预(与成功衰老相比
对照干预)在随机化后的3年时间间隔内减少认知能力下降。我们现在建议
继续跟踪实现队列另外3年(即直到第6年),以确定长期-
听力干预的长期效应(即,参与者在第0年被随机分配到HI)与成功
老龄化/延迟HI控制(即,参与者在第0年随机进入SA,并在第3年后提供HI
访问)对认知和大脑结果的影响。鉴于认知障碍通常反映出反应迟缓
随着病理改变的积累,HI在减缓这种下降方面的好处可能不会在
只有3年。因此,这一为期6年的队列跟踪调查将使我们能够充分评估更长时间的、累积的
HI对老年人的影响。这些调查结果将补充2023年的主要试验结果,并直接告知
围绕可能使用听力干预以降低ADRD风险的临床和政策决定。这
拟议的研究有以下目标:目标1确定HI与SA/延迟HI的长期影响
控制以下共同主要结局的比率:(A)认知下降和(B)事件轻度认知损害
(MCI)/痴呆。目的2确定HI与SA/延迟HI控制的长期效果。
脑核磁共振测量:(A)局部脑容量和(B)白质束完整性。次要目标:1)
调查影响HI治疗效果异质性的潜在因素;2)调查医疗保健
通过分析Medicare索赔数据,比较HI与SA/Delay HI控制组之间的支出和使用情况。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSEF CORESH其他文献
JOSEF CORESH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSEF CORESH', 18)}}的其他基金
Long-term effects of hearing intervention on brain health in the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) randomized study
老年人衰老和认知健康评估 (ACHIEVE) 随机研究中听力干预对大脑健康的长期影响
- 批准号:
10680434 - 财政年份:2022
- 资助金额:
$ 412.39万 - 项目类别:
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A
社区动脉粥样硬化风险 (ARIC) 研究 - 现场中心 - 任务令 01,任务区 A
- 批准号:
10788250 - 财政年份:2021
- 资助金额:
$ 412.39万 - 项目类别:
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A
社区动脉粥样硬化风险 (ARIC) 研究 - 现场中心 - 任务令 01,任务区 A
- 批准号:
10620984 - 财政年份:2021
- 资助金额:
$ 412.39万 - 项目类别:
Integrative Omics, Chronic Kidney Disease, and Adverse Outcomes in Older Adults
综合组学、慢性肾病和老年人的不良后果
- 批准号:
10163839 - 财政年份:2020
- 资助金额:
$ 412.39万 - 项目类别:
Integrative Omics, Chronic Kidney Disease, and Adverse Outcomes in Older Adults
综合组学、慢性肾病和老年人的不良后果
- 批准号:
10368118 - 财政年份:2020
- 资助金额:
$ 412.39万 - 项目类别:
ARIC - JHU FIELD CENTER - DIVERSITY SUPPLEMENT
ARIC - JHU 野外中心 - 多样性补充
- 批准号:
10054600 - 财政年份:2019
- 资助金额:
$ 412.39万 - 项目类别:
Aging, Cognition, and Hearing Evaluation in Elders (ACHIEVE) Randomized Trial
老年人的衰老、认知和听力评估 (ACHIEVE) 随机试验
- 批准号:
9986336 - 财政年份:2017
- 资助金额:
$ 412.39万 - 项目类别:
Aging, Cognition, and Hearing Evaluation in Elders (ACHIEVE) Randomized Trial
老年人的衰老、认知和听力评估 (ACHIEVE) 随机试验
- 批准号:
9287053 - 财政年份:2017
- 资助金额:
$ 412.39万 - 项目类别:
IGF::OT::IGF ATHEROSCLEROSIS IN RISK COMMUNITIES - FIELD CENTER - CORE STUDY OPERATIONS
IGF::OT::IGF 动脉粥样硬化风险社区 - 现场中心 - 核心研究操作
- 批准号:
10329837 - 财政年份:2016
- 资助金额:
$ 412.39万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 412.39万 - 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
- 批准号:
2601817 - 财政年份:2021
- 资助金额:
$ 412.39万 - 项目类别:
Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
- 批准号:
2029039 - 财政年份:2020
- 资助金额:
$ 412.39万 - 项目类别:
Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
- 批准号:
9888417 - 财政年份:2019
- 资助金额:
$ 412.39万 - 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
- 批准号:
17K11318 - 财政年份:2017
- 资助金额:
$ 412.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 412.39万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 412.39万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 412.39万 - 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
- 批准号:
BB/M50306X/1 - 财政年份:2014
- 资助金额:
$ 412.39万 - 项目类别:
Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
- 批准号:
288272 - 财政年份:2013
- 资助金额:
$ 412.39万 - 项目类别:
Miscellaneous Programs














{{item.name}}会员




